About aldeyra therapeutics - ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities related to general business planning, including raising capital. It focuses on the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
ALDX At a Glance
Aldeyra Therapeutics, Inc.
131 Hartwell Avenue
Lexington, Massachusetts 02421
| Phone | 1-781-761-4904 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -33,846,661.00 | |
| Sector | Health Technology | Employees | 8 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ALDX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 7.043 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -7.328 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.061 |
ALDX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -4,230,832.625 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ALDX Liquidity
| Current Ratio | 2.544 |
| Quick Ratio | 2.544 |
| Cash Ratio | 2.519 |
ALDX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -38.317 |
| Return on Equity | -58.733 |
| Return on Total Capital | -56.618 |
| Return on Invested Capital | -51.97 |
ALDX Capital Structure
| Total Debt to Total Equity | 35.096 |
| Total Debt to Total Capital | 25.979 |
| Total Debt to Total Assets | 21.552 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |